Published Paper Details:

This study focuses on the preparation and evaluation of an oral in-situ gel formulation of Sitagliptin Phosphate, aimed at improving the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances glycemic control when used as monotherapy or in combination with other antidiabetic agents. The innovative in-situ gel system is designed for ease of administration and improved patient compliance, forming a gel upon contact with the gastric environment. This formulation leverages the benefits of sustained drug release, reduced dosing frequency, and enhanced bioavailability, addressing the challenges posed by conventional dosage forms. The study employed preformulation assessments, including melting point determination and Fourier transform infrared spectroscopy, to confirm the chemical integrity and compatibility of Sitagliptin with excipients. Viscosity measurements, pH tests, and floating behavior analyses were conducted to evaluate the gel's physical properties. Drug content uniformity and in vitro drug release studies were performed, revealing a controlled release profile suitable for maintaining therapeutic drug levels. The development of this in-situ gel system presents a promising approach to optimizing the therapeutic efficacy of Sitagliptin Phosphate, potentially improving clinical outcomes for patients with type 2 diabetes. The formulation's benefits, such as ease of administration, sustained drug release, and targeted delivery, underscore its potential as an effective oral therapeutic option.